Cargando…

The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial

Chronic hyperglycemia increases oxidative stress, activates inflammatory pathways and reduces nerve growth factor (NGF) among diabetic patients, which contribute to development of diabetic peripheral neuropathy (DPN). Tocotrienol-Rich Vitamin E (Tocovid) possesses potent antioxidant and anti-inflamm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ng, Yeek Tat, Phang, Sonia Chew Wen, Tan, Gerald Chen Jie, Ng, En Yng, Botross Henien, Nevein Philip, M. Palanisamy, Uma Devi, Ahmad, Badariah, Abdul Kadir, Khalid
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284602/
https://www.ncbi.nlm.nih.gov/pubmed/32456230
http://dx.doi.org/10.3390/nu12051522
_version_ 1783544505601884160
author Ng, Yeek Tat
Phang, Sonia Chew Wen
Tan, Gerald Chen Jie
Ng, En Yng
Botross Henien, Nevein Philip
M. Palanisamy, Uma Devi
Ahmad, Badariah
Abdul Kadir, Khalid
author_facet Ng, Yeek Tat
Phang, Sonia Chew Wen
Tan, Gerald Chen Jie
Ng, En Yng
Botross Henien, Nevein Philip
M. Palanisamy, Uma Devi
Ahmad, Badariah
Abdul Kadir, Khalid
author_sort Ng, Yeek Tat
collection PubMed
description Chronic hyperglycemia increases oxidative stress, activates inflammatory pathways and reduces nerve growth factor (NGF) among diabetic patients, which contribute to development of diabetic peripheral neuropathy (DPN). Tocotrienol-Rich Vitamin E (Tocovid) possesses potent antioxidant and anti-inflammatory properties which are postulated to target these pathogeneses in order to ameliorate DPN. This study aims to evaluate the effects of Tocovid on nerve conduction parameters and serum biomarkers among diabetic patients. This multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was conducted on 80 eligible participants. The intervention group (n = 39) was randomly allocated to receive 200 mg of Tocovid twice a day, and the control group (n = 41) received placebo twice a day. At the end of eight weeks, the nerve conduction parameters, as assessed by nerve conduction study, as well as serum biomarkers (NGF, malondialdehyde, vascular cell adhesion molecule 1, tumor necrosis factor receptor 1 and thromboxane B2) were compared between the two groups. Compared to placebo, Tocovid significantly improves the nerve conduction velocities of all nerves (+1.25 m/s, interquartile range [IQR] 3.35, p < 0.001, median nerve; +1.60 m/s, IQR 1.80, p < 0.001, sural nerve; +0.75 m/s, IQR 2.25, p < 0.001, tibial nerve). Meanwhile, the levels of serum NGF were significantly higher in the Tocovid group as compared to placebo at eight weeks post-intervention. Participants receiving Tocovid illustrated highly significant improvement in terms of nerve conduction velocities for all nerves tested after eight weeks of supplementation. In addition, Tocovid supplementation elevated the levels of serum NGF, in which its increase is postulated to reflect enhanced neuronal functions. This novel finding suggests that Tocovid could be a disease-modifying agent targeting serum NGF to improve nerve conduction velocities.
format Online
Article
Text
id pubmed-7284602
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72846022020-06-19 The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial Ng, Yeek Tat Phang, Sonia Chew Wen Tan, Gerald Chen Jie Ng, En Yng Botross Henien, Nevein Philip M. Palanisamy, Uma Devi Ahmad, Badariah Abdul Kadir, Khalid Nutrients Article Chronic hyperglycemia increases oxidative stress, activates inflammatory pathways and reduces nerve growth factor (NGF) among diabetic patients, which contribute to development of diabetic peripheral neuropathy (DPN). Tocotrienol-Rich Vitamin E (Tocovid) possesses potent antioxidant and anti-inflammatory properties which are postulated to target these pathogeneses in order to ameliorate DPN. This study aims to evaluate the effects of Tocovid on nerve conduction parameters and serum biomarkers among diabetic patients. This multicenter, prospective, randomized, double-blind, placebo-controlled clinical trial was conducted on 80 eligible participants. The intervention group (n = 39) was randomly allocated to receive 200 mg of Tocovid twice a day, and the control group (n = 41) received placebo twice a day. At the end of eight weeks, the nerve conduction parameters, as assessed by nerve conduction study, as well as serum biomarkers (NGF, malondialdehyde, vascular cell adhesion molecule 1, tumor necrosis factor receptor 1 and thromboxane B2) were compared between the two groups. Compared to placebo, Tocovid significantly improves the nerve conduction velocities of all nerves (+1.25 m/s, interquartile range [IQR] 3.35, p < 0.001, median nerve; +1.60 m/s, IQR 1.80, p < 0.001, sural nerve; +0.75 m/s, IQR 2.25, p < 0.001, tibial nerve). Meanwhile, the levels of serum NGF were significantly higher in the Tocovid group as compared to placebo at eight weeks post-intervention. Participants receiving Tocovid illustrated highly significant improvement in terms of nerve conduction velocities for all nerves tested after eight weeks of supplementation. In addition, Tocovid supplementation elevated the levels of serum NGF, in which its increase is postulated to reflect enhanced neuronal functions. This novel finding suggests that Tocovid could be a disease-modifying agent targeting serum NGF to improve nerve conduction velocities. MDPI 2020-05-23 /pmc/articles/PMC7284602/ /pubmed/32456230 http://dx.doi.org/10.3390/nu12051522 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ng, Yeek Tat
Phang, Sonia Chew Wen
Tan, Gerald Chen Jie
Ng, En Yng
Botross Henien, Nevein Philip
M. Palanisamy, Uma Devi
Ahmad, Badariah
Abdul Kadir, Khalid
The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial
title The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial
title_full The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial
title_fullStr The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial
title_full_unstemmed The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial
title_short The Effects of Tocotrienol-Rich Vitamin E (Tocovid) on Diabetic Neuropathy: A Phase II Randomized Controlled Trial
title_sort effects of tocotrienol-rich vitamin e (tocovid) on diabetic neuropathy: a phase ii randomized controlled trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7284602/
https://www.ncbi.nlm.nih.gov/pubmed/32456230
http://dx.doi.org/10.3390/nu12051522
work_keys_str_mv AT ngyeektat theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT phangsoniachewwen theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT tangeraldchenjie theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT ngenyng theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT botrosshenienneveinphilip theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT mpalanisamyumadevi theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT ahmadbadariah theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT abdulkadirkhalid theeffectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT ngyeektat effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT phangsoniachewwen effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT tangeraldchenjie effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT ngenyng effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT botrosshenienneveinphilip effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT mpalanisamyumadevi effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT ahmadbadariah effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial
AT abdulkadirkhalid effectsoftocotrienolrichvitaminetocovidondiabeticneuropathyaphaseiirandomizedcontrolledtrial